A Single-Center, Single-Arm Exploratory Clinical Trial of Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced Head and Neck Squamous Cell Carcinoma
Overview
- Phase
- Phase 2
- Intervention
- 3cycles (Toripalimab + cetuximab)
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Sponsor
- Wuhan Union Hospital, China
- Enrollment
- 33
- Locations
- 1
- Primary Endpoint
- Pathological Complete Response (pCR) Rate evaluated by investigators
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
Detailed Description
At present, the standard treatment for patients with operable locally advanced head and neck squamous cell carcinoma (HNSCC) is adjuvant radiotherapy with or without platinum-based synchronous chemotherapy after operation. However, the risk of recurrence, metastasis and death remains high in this population with this intense combination treatment regimen. Both EGFR monoclonal antibody and PD-1 inhibitors have proven the effect in advanced HNSCC. At the same time, cetuximab and PD-1 inhibitors have been reported to have a synergistic effect that may improve patient survival. This study aims to explore the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The age at the time of enrollment is more than 18 years old and less than 70 years old, both male and female.
- •Histologically diagnosed as squamous cell carcinoma of the mouth, oropharynx, hypopharynx or larynx; preoperative evaluation can be surgically resected.
- •Have the following high-risk recurrence conditions as defined in the 8th edition of the American Joint Committee on Cancer \[AJCC\] Guidelines: a)HPV-negative disease, stage III, IVa, according to the head and Neck Tumor/lymph node/metastasis (TNM) guidelines; b)non-oropharyngeal HPV-positive disease, stages III, IVa, IVb, according to head and neck TNM guidelines.
- •No previous treatment for HNSCC.
- •Have at least one evaluable target lesion according to RECIST version 1.1 criteria.
- •The Eastern Cancer Cooperation Organization (ECOG) physical fitness score was 0 or
- •Major organs have normal function, the following criteria are met:
- •The standard of blood routine examination（(not transfused or receiving component blood within 14 days prior to testing)：hemoglobin (HB) ≥ 9g/dL；absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets (PLT) ≥100×10\^9/L.
- •Biochemical examination: serum total bilirubin (TBIL) \<1.5 times the upper limit of normal value(ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT)\<2.5 ULN; serum creatinine≤ULN and endogenous creatinine clearance\>50 mL/min (Cockcroft-Gault formula) Gault formula).
- •Signed written informed consent.
Exclusion Criteria
- •prior treatment with EGFR/PD-1/PD-L1/PD-L2/CD137/CTLA-4 antibodies(including ipilimumab) or activating or inhibitory agents targeting T-cell receptors.
- •Major surgery within 4 weeks before enrollment.
- •Proven allergic to EGFR monoclonal antibody, PD-1 antibody or its excipients.
- •Any active autoimmune disease or history of autoimmune disease (e.g., the following: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (can be included after effective hormone replacement therapy), etc; patients with vitiligo or asthma in complete remission in childhood may be included, adults patients with asthma who do not need any intervention and require medical intervention with bronchodilators may be included) .
- •Previous or co-existing malignancies (except those that have been cured and have survived cancer-free for more than 5 years, such as basal cell carcinoma of the skin, carcinoma in situ of the cervix, and papillary carcinoma of the thyroid).
- •Failure to control cardiac clinical symptoms or disease, e.g., the following: a) patients with NYHAII or above heart failure, b) unstable angina pectoris c) patients with myocardial infarction within 1 year, d) patients with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention.
- •Subjects requiring systemic treatment with corticosteroids (\> 10mg/ day prednisone efficacy dose) or other immunosuppressants within 14 days prior to administration of the study drug were allowed to use inhaled or topical steroids and adrenal hormone replacement at a dose\>10mg/day prednisone efficacy dose in the absence of active autoimmune disease.
- •Have active infections that require treatment.
- •Have a congenital or acquired immune deficiency (such as HIV infection), active hepatitis B (HBV-DNA≥10\^3 copy number/ml), or hepatitis C (hepatitis C antibody positive and HCV-RNA above the lower detection limit of analytical methods).
- •The patient has received other treatment before.
Arms & Interventions
Neoadjuvant therapy+Surgery+Adjuvant therapy+Consolidation therapy
Participants receive totally 3 cycles of neoadjuvant therapy (Toripalimab+cetuximab), then radical treatment(surgery). After surgery, Participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation. Then, participants receive consolidation therapy of Toripalimab.
Intervention: 3cycles (Toripalimab + cetuximab)
Neoadjuvant therapy+Surgery+Adjuvant therapy+Consolidation therapy
Participants receive totally 3 cycles of neoadjuvant therapy (Toripalimab+cetuximab), then radical treatment(surgery). After surgery, Participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation. Then, participants receive consolidation therapy of Toripalimab.
Intervention: Surgery
Neoadjuvant therapy+Surgery+Adjuvant therapy+Consolidation therapy
Participants receive totally 3 cycles of neoadjuvant therapy (Toripalimab+cetuximab), then radical treatment(surgery). After surgery, Participants receive radiotherapy or chemoradiotherapy according to the pathological results of the operation. Then, participants receive consolidation therapy of Toripalimab.
Intervention: Radiotherapy or chemoradiotherapy
Outcomes
Primary Outcomes
Pathological Complete Response (pCR) Rate evaluated by investigators
Time Frame: up to 13 weeks after neoadjuvant
pCR rate is defined as the percentage of participants having an absence of residual invasive cancer in resected tumour and lymph nodes following completion of neoadjuvant therapy.
Secondary Outcomes
- Objective Response Rate (ORR) evaluated by investigators(Up to 3 years)
- 2 years Event-free survival (EFS) Rate evaluated by investigators(EFS Up to 3 years)
- Incidence of AEs/SAEs(Up to 3 years)
- Major Pathological Response (MPR) Rate evaluated by investigators(up to 13 weeks after neoadjuvant)
- 2 years Disease-free survival (DFS) Rate evaluated by investigators(DFS Up to 3 years)
- Organ Retention Rate(Up to 3 years)